[Perphenazine enanthate. Results of a 1-year open multicenter study]
P Baruch1, S Brion, P Broussolle
1Service de Psychiatrie (Adultes), Hôpital de la Salpêtrière, Paris.
L'Encephale
|September 1, 1989
Summary
This study evaluated perphenazine enanthate, a long-acting antipsychotic, in 144 patients over 12 months. While overall improvement was similar across conditions, schizophrenia required longer treatment for full assessment of this neuroleptic drug.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Trials
Background:
- Perphenazine enanthate is a sustained-release neuroleptic medication.
- Assessing the efficacy of long-acting antipsychotics requires understanding treatment duration.
- Schizophrenia and chronic delusions are significant psychiatric conditions.
Purpose of the Study:
- To evaluate the one-year therapeutic outcomes of perphenazine enanthate.
- To compare treatment response onset across different psychiatric diagnoses.
- To determine the optimal assessment period for sustained-release neuroleptic efficacy.
Main Methods:
- Open-label, multicenter trial involving 240 patients, with 144 followed for 12 months.
- Utilized the Brief Psychiatric Rating Scale (BPRS) for efficacy assessment.
- Monitored adverse reactions typical of sustained-release neuroleptics.
Main Results:
- 12-month treatment showed similar percentage improvement in BPRS scores for chronic delusions, paranoid schizophrenia, and hebephrenia.
- Therapeutic activity onset varied: rapid within 4 months for chronic delusions.
- Schizophrenia showed a more progressive improvement, indicating a need for extended treatment duration.
Conclusions:
- Perphenazine enanthate demonstrates efficacy across studied conditions, but treatment duration impacts assessment.
- Prolonged treatment is necessary to fully evaluate the therapeutic potential of sustained-release neuroleptics in schizophrenia.
- Individualized assessment periods are crucial for optimizing neuroleptic therapy.
More Related Videos
14:39Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
07:35Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...